What is claimed is:

1. The pharmaceutically acceptable salt selected from the group consisting of:

3-((3-chlorophenyl)amino)-5-((4-hydroxybenzyl)amino)-3*H*-pyrazole-4-carboxamide hydrochloride;

5-((4-hydroxybenzyl)amino)-3-((4-(4-methylpiperazin-1-yl)phenyl)amino)-3*H*-pyrazole-4-carboxamide hydrochloride;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinomethyl)phenyl)amino)-3*H*-pyrazole-4-carboxamide hydrochloride;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinophenyl)amino)-3*H*-pyrazole-4-carboxamide hydrobromide;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinophenyl)amino)-3*H*-pyrazole-4-carboxamide hydrochloride;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinophenyl)amino)-3*H*-pyrazole-4-carboxamide, acetic acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinophenyl)amino)-3*H*-pyrazole-4-carboxamide, formic acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinophenyl)amino)-3*H*-pyrazole-4-carboxamide, camphorsulfonic acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinophenyl)amino)-3*H*-pyrazole-4-carboxamide, phosphoric acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinophenyl)amino)-3*H*-pyrazole-4-carboxamide, sulfuric acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinophenyl)amino)-3*H*-pyrazole-4-carboxamide, trifluoroacetic acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-morpholinophenyl)amino)-3*H*-pyrazole-4-carboxamide, tartaric acid salt;

5-((4-hydroxybenzyl)amino)-3-((6-morpholinopyridin-3-yl)amino)-3*H*-pyrazole-4-carboxamide hydrochloride;

5-((4-hydroxybenzyl)amino)-3-((6-morpholinopyridin-3-yl)amino)-3*H*-pyrazole-4-carboxamide, methanesulfonic acid salt;

5-((4-hydroxybenzyl)amino)-3-((6-morpholinopyridin-3-yl)amino)-3*H*-pyrazole-4-carboxamide, phosphoric acid salt;

5-((4-hydroxybenzyl)amino)-3-((6-morpholinopyridin-3-yl)amino)-3*H*-pyrazole-4-carboxamide, sulfuric acid salt;

5-((4-hydroxybenzyl)amino)-3-((6-morpholinopyridin-3-yl)amino)-3*H*-pyrazole-4-carboxamide, trifluoroacetic acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-(pyridin-2-yl)phenyl)amino)-3*H*-pyrazole-4-carboxamide, camphorsulfonic acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-(pyridin-2-yl)phenyl)amino)-3*H*-pyrazole-4-carboxamide, phosphoric acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-(pyridin-2-yl)phenyl)amino)-3*H*-pyrazole-4-carboxamide, sulfuric acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-(pyridin-2-yl)phenyl)amino)-3*H*-pyrazole-4-carboxamide, tartaric acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-(pyridin-2-yl)phenyl)amino)-3*H*-pyrazole-4-carboxamide, *p*-toluenesulfonic acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-(pyridin-2-yl)phenyl)amino)-3*H*-pyrazole-4-carboxamide, trifluoroacetic acid salt;

5-((4-hydroxybenzyl)amino)-3-((4-(4-isopropylpiperazin-1-yl)phenyl)amino)-3*H*-pyrazole-4-carboxamide hydrochloride;

5-((4-hydroxybenzyl)amino)-3-((4-(4-isopropylpiperazin-1-yl)phenyl)amino)-3*H*-pyrazole-4-carboxamide, phosphoric acid salt;

3-((4-(1*H*-imidazol-1-yl)phenyl)amino)-5-((4-hydroxybenzyl)amino)-3*H*-pyrazole-4-carboxamide hydrochloride;

3-((4-(1*H*-imidazol-1-yl)phenyl)amino)-5-((4-hydroxybenzyl)amino)-3*H*-pyrazole-4-carboxamide, acetic acid salt;

3-((4-(1*H*-imidazol-1-yl)phenyl)amino)-5-((4-hydroxybenzyl)amino)-3*H*-pyrazole-4-carboxamide, phosphoric acid salt and

3-((1*H*-indazol-5-yl)amino)-5-((4-hydroxybenzyl)amino)-3*H*-pyrazole-4-carboxamide hydrochloride;

and stereoisomers, enantiomers, mixtures of enantiomers, mixtures of diastereomers, and isotopic variants thereof; and pharmaceutically acceptable solvates, hydrates, and prodrugs thereof.

2. A pharmaceutical composition comprising of the pharmaceutically acceptable salt of claim 1, and one or more pharmaceutically acceptable excipients.

3. The pharmaceutical composition of claim 2, wherein the composition is formulated for single dose administration.

4. The pharmaceutical composition of claim 2 or 3, wherein the composition is formulated as oral, parenteral, or intravenous dosage form.

5. The pharmaceutical composition of claim 4, wherein the oral dosage form is a tablet or a capsule.

6. The pharmaceutical composition of any of claims 2-5, further comprising a second therapeutic agent.

7. Use of pharmaceutically acceptable salt of claim 1or the pharmaceutical composition of any of claims 2 to 6 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of one or more symptoms of a RC kinase-mediated disorder, disease, or condition in a subject.

8. Use of pharmaceutically acceptable salt of claim 1 or the pharmaceutical composition of any of claims 2 to 6 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of one or more symptoms of a RC kinase-mediated eosinophil-related disorder, disease, or condition in a subject.

9. Use of pharmaceutically acceptable salt of claim 1 or the pharmaceutical composition of any of claims 2 to 6 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of one or more symptoms of a RC kinase-mediated basophil-related disorder, disease, or condition in a subject.

10. Use of pharmaceutically acceptable salt of claim 1 or the pharmaceutical composition of any of claims 2 to 6 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of a RC kinase-mediated mast cell-related disorder, disease, or condition in a subject.

11. Use of pharmaceutically acceptable salt of claims 1 or the pharmaceutical composition of any of claims 2 to 6 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of an inflammatory disease in a subject.

12. The use of claim 11, wherein the disorder, disease, or condition is selected from the group consisting of asthma, allergic asthma, exercise induced asthma, allergic rhinitis, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, contact dermatitis, conjunctivitis, allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, Crohn’s disease, mastocytosis, hyper IgE syndrome, systemic lupus erythematous, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, Churg-Strauss syndrome, sinusitis, basophilic leukaemia, chronic urticaria, basophilic leukocytosis, eczema, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, and cardiovascular disorders.


13. The use of claim 12, wherein the disorder, disease, or condition is asthma, exercise induced asthma, allergic rhinitis, atopic dermatitis, chronic obstructive pulmonary disease, or allergic conjunctivitis.

14. The use of claims 7 to 13, further comprising of a second therapeutic agent.

15. Use of a pharmaceutically acceptable salt of claim 1 or the pharmaceutical composition of any of claims 2 to 6 in the manufacture of a medicament for modulating RC kinase activity.

16. Use of a pharmaceutically acceptable salt of claim 1 or the pharmaceutical composition of any of claims 2 to 6 in the manufacture of a medicament for modulating CCR3 activity.

17. A compound formula:



or a stereoisomer, enantiomer, mixture of enantiomers, mixture of diastereomers, or isotopic variant thereof; of a pharmaceutically acceptable solvate, hydrate, or prodrug thereof.

18. A pharmaceutical composition comprising the compound of claim 17, and one or more pharmaceutically acceptable excipients.

19. The pharmaceutical composition of claim 18, wherein the composition is formulated for single dose administration.

20. The pharmaceutical composition of claim 18 or 19, wherein the composition is formulated as oral, parenteral, or intravenous dosage form

21. The pharmaceutical composition of claim 20, wherein the oral dosage form is a tablet or a capsule.

22. The pharmaceutical composition of any of claims 18-21, further comprising a second therapeutic agent.

23. Use of the compound of claim 17 or the pharmaceutical composition of any of claims 18 to 22 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of a RC kinase-mediated disorder, disease, or condition in a subject.

24. Use of the compound of claim 17 or the pharmaceutical composition of any of claims 18 to 22 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of a RC kinase-mediated eosinophil-related disorder, disease, or condition in a subject.

25. Use of the compound of claim 17 or the pharmaceutical composition of any of claims 18 to 22 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of a RC kinase-mediated basophil-related disorder, disease, or condition in a subject.

26. Use of the compound of claim 17 or the pharmaceutical composition of any of claims 18 to 22 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of a RC kinase-mediated mast cell-related disorder, disease, or condition in a subject.

27. Use of the compound of claim 17 or the pharmaceutical composition of any of claims 18 to 22 in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of one or more symptoms of an inflammatory disease in a subject.

28. The use of claim 27, wherein the disorder, disease, or condition is selected from the group consisting of asthma, allergic asthma, exercise induced asthma, allergic rhinitis, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, contact dermatitis, conjunctivitis, allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, mastocytosis, hyper IgE syndrome, systemic lupus erythematous, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, Churg-Strauss syndrome, sinusitis, basophilic leukaemia, chronic urticaria, basophilic leucocytosis, eczema, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, and cardiovascular disorders.

29. The use of claim 28, wherein the disorder, disease, or condition is asthma, exercises induced asthma, allergic rhinitis, atopic dermatitis, chronic obstructive pulmonary disease, or allergic conjunctivitis.

30. The use of claims 23 to 29, further comprising a second therapeutic agent.

31. Use of the compound of claim 17 or the pharmaceutical composition of any of claims 18 to 22 in the manufacture of a medicament for modulating RC kinase activity.

32. Use of the compound of claim 17 or the pharmaceutical composition of any of claims 18 to 22 in the manufacture of a medicament for modulating CCR3 activity.